TWST earnings analysis
What we found in TWST's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Twist delivered Q3 FY26 revenue of $118.376 million, up 23.2% year over year, supported by 39% growth in DNA synthesis and protein solutions and 12% growth in NGS applications. Profitability remains the key offset: gross margin declined 0.6 percentage points to 52.8%, operating loss widened to $36.3 million, and reported EPS was negative $0.56. Liquidity of $166.8 million supports the stated more-than-12-month runway, but operating cash use of $41.258 million and capex of $27.611 million in the first nine months keep cash burn and potential ATM dilution in focus.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth remained strong
- Q3 revenue rose 23.2% year over year to $118.376 million from $96.057 million. Revenue also increased sequentially from $111 million in Q2 FY26 to $118.376 million in Q3 FY26.
- Both product categories expanded
- DNA synthesis and protein solutions revenue increased 39% to $56.571 million, while NGS applications grew 12% to $61.805 million. Therapeutics revenue increased to $40.413 million from $27.048 million, a major contributor to growth.
- Volume and customer base increased
- The company shipped approximately 369,000 genes, up 56% from approximately 237,000 in the prior-year quarter, while purchasing customers increased to approximately 2,664 from approximately 2,484.
- Gross margin held near 53%
- Gross margin was 52.8%, down only 0.6 percentage points from 53.4% a year earlier despite a 25% increase in cost of revenue to $55.922 million. Sequentially, margin improved from 51.6% in Q2 FY26.
- Cost actions targeted for Q4
- Management expects SG&A expense to moderate in Q4 FY26 following cost-saving initiatives; Q3 SG&A was $80.709 million, or 68% of revenue.
- Liquidity supports near-term operations
- Liquidity totaled $166.8 million at June 30, 2026, comprising $117.4 million of cash and cash equivalents and $49.4 million of short-term investments. The company states this is sufficient for more than 12 months under its current business plan.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operating losses increased with SG&A
- The operating loss widened 20.5% year over year to $36.3 million, despite the 23.2% increase in revenue. Operating margin was negative 30.7%, while SG&A rose 27% to $80.709 million.
- Cash burn and capex remain elevated
- Net cash used in operations rose 15.2% to $41.258 million for the first nine months of FY26. Combined with $27.611 million of property-and-equipment purchases, this implies approximately $68.869 million of nine-month free-cash-flow usage.
- Working capital consumed cash
- Accounts receivable increased by $8.5 million and inventories increased by $6.9 million during the first nine months, partly reflecting revenue growth and inventory built for anticipated demand. These working-capital uses contributed to operating cash outflow.
- Litigation cost and accumulated deficit
- The company recorded $7.205 million of litigation settlement costs, net of recoveries, during the first nine months of FY26 and reported an accumulated deficit of $1.4292 billion at June 30, 2026.
- Potential equity dilution from ATM
- The company has a $200.0 million at-the-market equity program, with its full capacity available at June 30, 2026. While no shares had been sold, future usage could dilute shareholders.
- No new risk-factor changes disclosed
- The filing states that there were no material changes to risk factors from the November 17, 2025 Form 10-K. The principal disclosed liquidity constraint remains ongoing losses, including a $109.6 million net loss for the first nine months of FY26.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.56
- Gross margin
- 52.8%
- Operating margin
- -30.7%
- Segment
- One reportable segment; product revenue: DNA synthesis and protein solutions $56.571 million (48% of revenue), NGS applications $61.805 million (52% of revenue).
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance. Management expects selling, general and administrative expense to moderate in Q4 fiscal 2026 from cost-saving initiatives.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 4, 2026
- Twist Bioscience reported strong Q2 FY26 results with revenue of $110.7 million, surpassing expectations of $107.7 million, showing a year-over-year increase of 19%. However, the company reported an EPS of -$0.59, which…
- 10-Q · February 2, 2026
- Twist reported quarterly revenue of $103,698 (in thousands), up $14,985 (16.9%) year-over-year and up ~$4,698 (4.7%) sequentially, with gross margin expanding to ~52.1% (Revenue $103,698; Cost of revenues $49,726).…
- 10-K · November 17, 2025
- Twist reported fiscal year 2025 revenue of $376.6 million driven by healthcare ($215.1M) and chemicals/materials ($93.2M) while continuing to invest in product expansion (Express products, NGS tools, antibody services).…
- 10-Q · August 4, 2025
- Twist reported quarterly revenue of $96,057,000 and delivered GAAP net income of $20,390,000 (diluted EPS $0.33) for the three months ended June 30, 2025, driven largely by a $48,847,000 gain on the sale of its DNA Data…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TWST makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever